Human immunodeficiency virus type 1 (HIV-1) antibody testing: analytic sensitivity and analytic specificity of enzyme immunoassay (EIA) results.

Important note: Information in this article was accurate in 1992. The state of the art may have changed since the publication date.

Human immunodeficiency virus type 1 (HIV-1) antibody testing: analytic sensitivity and analytic specificity of enzyme immunoassay (EIA) results.

Abstr Annu Meet Am Soc Microbiol. 1991 May 5-9;91:336 (abstract no. T-13). Unique Identifier : AIDSLINE ASM91/0260292
Cross GD; Schalla WO; Blumer SO; Hearn TL; Valdiserri RO; Centers for Disease Control, Atlanta, GA.

Abstract: Laboratories enrolled in the CDC model performance evaluation program for HIV-1 antibody testing reported EIA results after testing HIV-1 performance evaluation samples sent them in February and May 1990. The panels contained 10 individual samples that were either HIV-1 antibody-negative, antibody-positive, or indeterminate; some samples were blind duplicates within the panel. Laboratories reported 1.3% false-reactive interpretations (analytic specificity: 98.7%) for the antibody-negative samples, compared with 0.3% false-nonreactive interpretatious (analytic sensitivity: 99.7%) for the positive group 1 samples (reactive using the WB interpretive criteria endorsed by the Association of State and Territorial Public Health Laboratory Directors/Centers for Disease Control [ASTPHLD/CDC] and by the Food and Drug Aministration/Du Pont [FDA/Du Pont]), 0.5% false-nonreactive interpretations (analytic sensitivity: 99.5%) for the positive group 2 samples (reactive by ASTPHLD/CDC, indeterminate by FDA/Du pont criteria), and 1.9% false-nonreactive interpretations (analytic sensitivity: 98.1%) for the indeterminate samples (indeterminate by ASTPHLD/CDC and FDA/Du Pont criteria).

Keywords: Enzyme-Linked Immunosorbent Assay Human HIV Antibodies/*ANALYSIS HIV-1/*IMMUNOLOGY Predictive Value of Tests Reproducibility of Results Sensitivity and Specificity ABSTRACT
920830
M9281057

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1992. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1992. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .